Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia

Christopher Arthur1
Jaroslav Cermak2
Jacques Delaunay3
Jiří Mayer4
Grzegorz Mazur5
Xavier Thomas6
Agnieszka Wierzbowska7
Mark M Jones8
Erhan Berrak8
Hagop Kantarjian9

1Department of Haematology, Royal North Shore Hospital, Sydney, NSW, Australia; 2Institute of Hematology and Blood Transfusion, Prague, Czech Republic; 3Department of Clinical Hematology, University of Nantes, Nantes, France; 4Department of Internal Medicine, Masaryk University Hospital Brno, Central European Institute of Technology, Brno, Czech Republic; 5Department of Hematology, Wrocław Medical University, Wrocław, Poland; 6Department of Hematology, Édouard Herriot Hospital, Lyon, France; 7Copernicus Memorial Hospital, Łódź, Poland; 8Oncology Product Creation Unit, Eisai Inc., Woodcliff Lake, NJ, USA; 9Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Background: In a Phase III trial, 485 patients (≥65 years) with newly diagnosed acute myeloid leukemia received decitabine 20 mg/m² intravenously for 5 days every 4 weeks or a treatment choice (supportive care or cytarabine 20 mg/m² subcutaneously for 10 days every 4 weeks).

Materials and methods: We summarized overall and progression-free survival by baseline white blood cell count using two analyses: <1, 1–5, >5×10^9/L; ≤10 or >10×10^9/L.

Results: There were 446 deaths (treatment choice, n=227; decitabine, n=219). Median overall survival was 5.0 (treatment choice) versus 7.7 months (decitabine; nominal P=0.037). Overall survival differences between white blood cell groups were not significant; hazard ratios (HRs) favored decitabine. Significant progression-free survival differences favored decitabine for groups 1–5×10^9/L (P=0.005, HR =0.67), greater than 5×10^9/L (P=0.027, HR =0.71), and up to 10×10^9/L (P=0.003, HR =0.72).

Conclusion: There was a trend toward improved outcome with decitabine, regardless of baseline white blood cell count.

Keywords: decitabine, acute myeloid leukemia, prognosis, leukemia, adult

Introduction
Each year in the US, approximately 12,330 new cases of acute myeloid leukemia (AML) are reported, and approximately 8,950 patients die from this disease.1 Approximately 18,000 new cases of AML are reported annually in the EU.2 The incidence of AML is increasing as the population ages,3 yet limited treatment options exist for older patients, particularly those with comorbidities.4 Recent updates of international treatment guidelines for AML5,6 now include low-intensity cytarabine, 5-azacytidine, and decitabine as therapeutic options.

A hypomethylating agent, decitabine was approved by the European Medicines Agency in 2012 for the treatment of patients ≥65 years of age with newly diagnosed de novo and secondary AML.6 It is approved by the US Food and Drug Administration for use in patients with previously treated and untreated de novo and secondary myelodysplastic syndrome of all French–American–British subtypes and intermediate-1, intermediate-2, and high-risk groups as categorized using the International Prognostic Scoring System.7 In previous Phase II studies, decitabine 20 mg/m² administered as a 1-hour intravenous infusion either daily for 5 consecutive
days every 4 weeks or on days 1–10 every 4 weeks demonstrated activity in older patients (aged 60 years) with AML and poor- or intermediate-risk cytogenetics.5,9

In a large Phase III trial (n=485), patients aged 65 years or older with newly diagnosed AML received a 1-hour intravenous infusion of decitabine 20 mg/m² for 5 consecutive days every 4 weeks or a treatment choice, with physician’s advice, of either supportive care or cytarabine 20 mg/m² subcutaneous injection for 10 consecutive days every 4 weeks.10 Enrolled patients were required to have a white blood cell (WBC) count below 40×10⁹/L, although because of protocol deviations, some patients who had WBC counts greater than 40×10⁹/L were enrolled. Decitabine-treatment benefit (as measured by overall survival [OS]) was more evident in patients with high baseline bone marrow blasts (>30%) and across all WBC counts.10 If low-dose hypomethylating agents induce an antileukemic action through differentiation, it would be expected that the more proliferative AML would respond poorly; however, responses favoring decitabine across all WBC counts in this study suggested that proliferation rates were not a determining factor in decitabine response. This post hoc analysis was undertaken to assess the relationship between baseline WBC count and survival outcomes in this study.

**Materials and methods**

OS and progression-free survival (PFS) were summarized by baseline WBC count subgroups (first analysis, <1, 1–5, and >5×10⁹/L; second analysis, ≤10×10⁹/L or >10×10⁹/L), i.e., WBC counts at start of therapy. Statistical comparisons were made using log-rank tests and hazard ratios (HRs), along with two-sided 95% confidence intervals from a Cox regression model; HRs less than 1 indicated an advantage for decitabine. Both the log-rank test and Cox regression were stratified (as was done for the primary analyses of the study data) by age (<70 years, ≥70 years), cytogenetic risk (intermediate, poor), and Eastern Cooperative Oncology Group (ECOG) performance status (0–1, 2). Median survival and PFS were estimated from unadjusted Kaplan–Meier product-limit estimates.11

**Results**

**Patients**

A total of 485 patients aged 65 years or older with newly diagnosed AML were randomized to treatment with either decitabine (n=242) or treatment choice (n=243 [cytarabine, n=215; supportive care, n=28]). At baseline, the median age of patients in each of the treatment groups was 73 years.10

In the decitabine and treatment-choice groups, respectively, 64% and 65% of patients had de novo AML, time since AML diagnosis was 14 days (range 3–346) and 15 days (range 0–398), and 63% and 64% had intermediate-risk disease. Median WBC count was 3.10×10⁹/L (range 0.3–127.0) in the decitabine group and 3.69×10⁹/L (range 0.5–80.9) in the treatment-choice group, and 44% and 42% of patients, respectively, had more than 50% bone marrow blasts. The primary analysis for this study was based on a clinical cutoff date in 2009, at which time 396 deaths had occurred. For this post hoc analysis of the intent-to-treat population, a mature data set using a 2010 clinical cutoff was used; at that time, 446 deaths had occurred (treatment choice, n=227; decitabine, n=219).10

**Survival outcomes**

The primary efficacy analysis (in October 2009) showed a nonsignificant trend toward an OS benefit with decitabine (median 7.7 versus 5.0 months for treatment choice). At the 2010 clinical cutoff, the median (95% confidence interval) OS was 5.0 months (4.3–6.3) for patients in the treatment-choice group and 7.7 months (6.2–9.2) for those in the decitabine group (HR=0.82, 95% confidence interval 0.68–0.99; nominal P=0.037).10

**Relationship between survival and baseline WBC counts**

Overall, median baseline WBC counts were relatively low in this patient population (Table 1), which was expected, as the exclusion criteria required patients to have WBC counts less than 40×10⁹/L.10 For each of the baseline WBC-count subgroups of less than 1, 1–5, and greater than 5×10⁹/L, differences in OS for the treatment-choice group compared with the decitabine group were not significant, but HRs favored decitabine in each of these WBC-count subgroups. A significant difference in PFS in favor of decitabine was observed in patients with baseline WBC counts of 1–5×10⁹/L (P=0.005) and >5×10⁹/L (P=0.028). All HRs again favored decitabine for each of these WBC-count subgroups (Table 1).11

Regarding the baseline WBC-count subgroup of up to 10×10⁹/L or greater than 10×10⁹/L, no significant difference was found between treatment groups in OS for either subgroup (Table 1). A significant difference (P=0.003) in PFS in favor of decitabine was found between treatment groups for patients with a baseline WBC count of up to 10×10⁹/L.

Findings for OS and PFS by treatment group for patients with baseline WBC up to 10×10⁹/L and greater than 10×10⁹/L are given in Kaplan–Meier curves (Figure 1).
For patients with baseline WBC counts up to $10^{10}/L$, no significant difference in median OS was found between the decitabine and treatment-choice groups. Similarly, no significant difference in median OS was observed between groups for patients with WBC counts greater than $10^{10}/L$ (Figure 1A).

No significant difference in median PFS between the decitabine and treatment-choice groups was seen for patients with baseline WBC counts higher than $10^{10}/L$ (Figure 1B). However, a significant difference between the groups was found for patients with baseline WBC counts of up to $10^{10}/L$ ($P=0.003$).11

### Discussion

This post hoc analysis of data from a large Phase III trial of patients aged 65 years or older with newly diagnosed AML found that the OS and PFS data were consistent with the overall results of the trial.10 HRs indicated a trend toward improved survival outcome with decitabine, regardless of baseline WBC count, in this older patient population. Significant differences between treatment groups for PFS were found in several baseline WBC-count subgroups (1–5, >5, and $\leq 10^{10}/L$). The lack of significance for an OS or PFS benefit in the groups with baseline WBC counts lower than $10^{10}/L$ may have been related to the smaller number of patients (treatment choice, $n=22$; decitabine, $n=25$) in these groups. In addition, it was noted that WBC counts were lower than expected in the AML population, perhaps due to the advanced age of the study group.

In a recent retrospective study in older patients ($>60$ years) with AML, a peripheral blast count of $\geq 0.1\times 10^{9}/L$ (indicative of more proliferative disease) was reported to be predictive of a poorer outcome with best supportive care or non-intensive chemotherapy compared with intensive chemotherapy, whereas patients with less proliferative disease ($<0.1\times 10^{9}/L$) had similar outcomes to best supportive care and intensive chemotherapy.12 Similarly, a previous Phase II study of the same decitabine regimen used in our analysis in patients aged 60 years or older with AML and poor- or intermediate-risk cytogenetics demonstrated that complete responses were highest in patients with the lowest presenting peripheral

| Outcome | White blood cell count $\times 10^{9}/L$ | Median for treatment choice, months n/N | Median for decitabine, months n/N | Nominal P-value $^c$ HR (95%, CI) $^a$
| --- | --- | --- | --- | ---
| Overall survival | All patients | 5.0 | 7.7 | $P=0.037$
| | <1 | 227/243 | 219/242 | HR = 0.82 (0.68, 0.99)
| | 4.9 | 8.6 | 8.5 | $P=0.640$
| | 1–5 | 20/22 | 22/25 | HR = 0.85 (0.42, 1.70)
| | 5.9 | 9.5 | 9.0 | $P=0.079$
| | >5 | 106/115 | 104/119 | HR = 0.78 (0.58, 1.03)
| | 4.3 | 6.3 | 6.1 | $P=0.180$
| | 94/99 | 88/93 | HR = 0.82 (0.60, 1.10)
| | $\leq 10$ | 5.7 | 8.6 | $P=0.083$
| | >10 | 161/180 | 160/181 | HR = 0.82 (0.66, 1.03)
| | 4.0 | 6.5 | 6.3 | $P=0.101$
| | 53/56 | 54/56 | HR = 0.71 (0.47, 1.07)
| Progression-free survival | All patients | 2.1 | 3.7 | $P=0.002$
| | <1 | 235/243 | 229/242 | HR = 0.74 (0.61, 0.89)
| | 2.2 | 5.5 | 5.5 | $P=0.914$
| | 1–5 | 20/22 | 24/25 | HR = 0.96 (0.48, 1.93)
| | 2.9 | 3.8 | 3.7 | $P=0.005$
| | >5 | 110/115 | 111/119 | HR = 0.67 (0.51, 0.89)
| | 2.1 | 3.4 | 3.4 | $P=0.028$
| | 98/99 | 89/93 | HR = 0.71 (0.53, 0.97)
| | $\leq 10$ | 2.2 | 3.8 | $P=0.003$
| | >10 | 173/180 | 169/181 | HR = 0.72 (0.57, 0.90)
| | 2.1 | 3.5 | 3.5 | $P=0.025$
| | 55/56 | 55/56 | HR = 0.76 (0.50, 1.17)

Notes: $^a$Kaplan–Meier product-limit estimates; $^b$either supportive care or cytarabine; $^c$two-sided log-rank test stratified by age ($<70$, $\geq 70$ years), cytogenetic risk (intermediate, poor), and ECOG PS (0–1, 2); $^d$Cox regression model stratified by age ($<70$, $\geq 70$ years), cytogenetic risk (intermediate, poor), and ECOG PS (0–1, 2). HR $<1$ indicates advantage for decitabine.

Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance score; HR, hazard ratio.
Figure 1 Overall survival (A) and progression-free survival (B) by treatment group for patients with baseline white blood cell count greater than 10×10^9/L and up to 10×10^9/L.

Abbreviations: HR, hazard ratio; NS, not significant; OS, overall survival; PFS, progression-free survival; WBC, white blood cell.
blood absolute blast counts (29% for patients with blast counts \(< 1 \times 10^9/\text{L}\)). No complete responses occurred in patients with blast counts higher than \(10 \times 10^9/\text{L}\) (indicative of more proliferative disease).\(^8\) In comparison, the current analysis found responses to decitabine across all patient subgroups, using baseline WBC count as a measure of the degree of proliferative disease. Moreover, in the original study from which this subanalysis was conducted, decitabine responses were more evident in patients with high baseline bone marrow blasts (\(> 30\%\)) and across all WBC counts.\(^8\) These disparate findings may reflect the different methods used to measure the degree of proliferative disease (WBC count or peripheral blood absolute blast count) in older patients with AML. In addition, it is possible that response to decitabine may be determined by a combination of factors, including the level of WBCs, the number of nonmobilized bone marrow blasts, and the extent of blast infiltration into the peripheral blood.

These results may be limited by the fact that this was a post hoc analysis and because patient numbers in some WBC-count subgroups were small. In addition, OS data may have been confounded because patients might have received further treatment after study completion.

Nevertheless, these findings suggest that older patients with newly diagnosed AML may respond to decitabine therapy, regardless of their baseline WBC counts. Additional studies may further elucidate any relationship between baseline WBC levels and outcomes in this patient population.

Acknowledgments
These data were presented in part at the Annual Meeting of the American Society of Clinical Oncology, June 1–5, 2012, in Chicago, IL (abstract 6559). Clinicaltrials.gov identifier: NCT00260832. The original study and this analysis were funded by Eisai Inc. The authors thank Yvonne E Yarker, PhD, CMPP of Peloton Advantage for medical writing and editorial support, funded by Eisai Inc., and Yuhan Li, MS of Eisai Inc. for statistical analyses.

Disclosure
JD has acted as a consultant for Novartis and Genzyme. JM has acted as a consultant for and received research funding from Eisai, is a member of Eisai’s board of directors and serves on advisory committees for Eisai Inc. MMJ and EB are employees of Eisai. HK has received research funding from Eisai. The other authors report no conflicts of interest in this work.

References